Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
The HER-2/ neu oncogene is a member of the erb B-like oncogene family, and is related to, but distinct from, the epidermal growth factor receptor. This gene has been shown to be amplified in human breast cancer cell lines. In the current study, alterations of the gene in 189 primary human breast cancers were investigated. HER-2/ neu was found to be amplified from 2- to greater than 20-fold in 30% of the tumors. Correlation of gene amplification with several disease parameters was evaluated. Amplification of the HER-2/ neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer. It retained its significance even when adjustments were made for other known prognostic factors. Moreover, HER-2/ neu amplification had greater prognostic value than most currently used prognostic factors, including hormonal-receptor status, in lymph node-positive disease. These data indicate that this gene may play a role in the biologic behavior and/or pathogenesis of human breast cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CNVs are involved in a large number of complex human diseases such as Down’s syndrome (trisomy 21) and many cancers, for example HER2 gene amplification in breast cancer (BC) (1–5).”
From Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation (2012) · cites this paper as [5]
In the citing paper
“In a seminal study, Slamon et al. found that HER2 is amplified in about 20% of breast cancers (Slamon et al., 1987).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Slamon et al., 1987
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene
Greenberg, M. E., & Ziff, E. B. (1984) · Nature · doi:10.1038/311433a0 · Cited by 3,064
Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
Land, H., Parada, L. F., & Weinberg, R. A. (1983) · Nature · doi:10.1038/304596a0 · Cited by 2,804
Ullrich, A., Coussens, L., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W., Lee, J., Yarden, Y., Libermann, T. A., Schlessinger, J., et al. (1984) · Nature · doi:10.1038/309418a0 · Cited by 2,752
Self-citationClose similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences
Downward, J., Yarden, Y., Mayes, E., Scrace, G., Totty, N., Stockwell, P., Ullrich, A., Schlessinger, J., & Waterfield, M. D. (1984) · Nature · doi:10.1038/307521a0 · Cited by 2,516
Self-citationAmplification of N- myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage
Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E., & Bishop, J. M. (1984) · Science · doi:10.1126/science.6719137 · Cited by 2,262
Association of Multiple Copies of the N-myc Oncogene with Rapid Progression of Neuroblastomas
Seeger, R. C., Brodeur, G. M., Sather, H., Dalton, A., Siegel, S. E., Wong, K. Y., & Hammond, D. (1985) · New England Journal of Medicine · doi:10.1056/nejm198510313131802 · Cited by 2,010
Coussens, L., Yang-Feng, T. L., Liao, Y.-C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., et al. (1985) · Science · doi:10.1126/science.2999974 · Cited by 1,814
Self-citation
Research works printed but not linked: 1
- Maniatis, T., Molecular Cloning: A Laboratory Manual: 282 (1982).
Cited by
Items 801–900 of 1,056
Devilee, P., van den Broek, M., Kuipers-Dukshoorn, N., Kolluri, R., Khan, P. M., Pearson, P. L., & Cornelisse, C. J. (1989) · Genomics · doi:10.1016/0888-7543(89)90023-2 · Cited by 195
Johnston, S., Trudeau, M., Kaufman, B., Boussen, H., Blackwell, K., LoRusso, P., Lombardi, D. P., Ben Ahmed, S., Citrin, D. L., DeSilvio, M. L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9949 · Cited by 195
Heterogeneity within molecular subtypes of breast cancer
Turner, K. M., Yeo, S. K., Holm, T. M., Shaughnessy, E., & Guan, J. (2021) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00109.2021 · Cited by 197
Loda, M. F., Capodieci, P., Mishra, R., Yao, H. W., Corless, C. L., Grigioni, W. F., Wang, Y., Magi-Galluzzi, C., & Stork, P. A. (1996) · Europe PMC (PubMed Central) · Cited by 195
Emerging Targeted Therapies for HER2-Positive Breast Cancer
Mercogliano, M. F., Bruni, S., Mauro, F. L., & Schillaci, R. (2023) · Cancers · doi:10.3390/cancers15071987 · Cited by 194
“The HER2-positive (HER2+) subtype is defined by HER2 overexpression/amplification and accounts for ~20% of breast cancers [2], 25% of ovarian cancers [3], and 18% of gastric cancers [4].”
BackgroundThe HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy
Ross, J. S., & Fletcher, J. A. (1999) · Seminars in Cancer Biology · doi:10.1006/scbi.1998.0083 · Cited by 194
Dong, Y., Li, W., Gu, Z., Xing, R., Ma, Y., Zhang, Q., & Liu, Z. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201904860 · Cited by 194
Hoff, D. D. V., McGill, J. R., Forseth, B. J., Davidson, K. K., Bradley, T. P., Devanter, D. R. V., & Wahl, G. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.17.8165 · Cited by 194
Ma, C. X., Bose, R., Gao, F., Freedman, R. A., Telli, M. L., Kimmick, G., Winer, E., Naughton, M., Goetz, M. P., Russell, C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0900 · Cited by 193
Gama, A., Alves, A., & Schmitt, F. (2008) · Virchows Archiv · doi:10.1007/s00428-008-0644-3 · Cited by 193
“Despite HER2 recognition as a prognostic factor in human breast cancer [41, 46], the significance of HER2 overexpression in dogs with mammary carcinoma is still unclear.”
BackgroundThe Ascension of Targeted Covalent Inhibitors
Singh, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02134 · Cited by 193
Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells
Li, G., Guo, J., Shen, B.-Q., Yadav, D. B., Sliwkowski, M. X., Crocker, L. M., Lacap, J. A., & Phillips, G. D. L. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0296 · Cited by 193
“HER2 gene amplification occurs in approximately 20% of breast cancer and is associatedwith increased disease recurrence and poor prognosis (2).”
BackgroundNew paradigms for the treatment of cancer: The role of anti-angiogenesis agents
(2000) · Advances in Cancer Research · doi:10.1016/s0065-230x(00)79001-4 · Cited by 193
Fujimoto-Ouchi, K., Sekiguchi, F., Yasuno, H., Moriya, Y., Mori, K., & Tanaka, Y. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0337-z · Cited by 193
“The expression of HER2 in breast cancer is known to be a factor for poor prognosis [18].”
BackgroundInomata, M., Ochiai, A., Akimoto, S., Kitano, S., & Hirohashi, S. (1996) · PubMed · Cited by 193
Coon, J. S., Marcus, E., Gupta-Burt, S., SEELIG, S. A., Jacobson, K., Chen, S., RENTA, V., Fronda, G., & Preisler, H. D. (2002) · PubMed · Cited by 193
Rodrigues, G. A., & Park, M. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.11.6711 · Cited by 192
“Amplification and overexpression have been the most commonly described mechanisms of deregulation of RTKs identified in human tumors (53).”
BackgroundTargeted Cancer Therapies in the Twenty-First Century: Lessons From Imatinib
Stegmeier, F., Warmuth, M., Sellers, W. R., & Dorsch, M. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.297 · Cited by 192
Williams, M. D., Roberts, D., Blumenschein, G. R., Temam, S., Kies, M. S., Rosenthal, D. I., Weber, R. S., & El-Naggar, A. K. (2007) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3180caa099 · Cited by 192
“The data also show that the incidence of SDCs that overexpress HER-2 receptors is comparable to those previously reported in salivary and high-grade mammary carcinoma studies.(17,42,48,49) These findings together with the hormonal receptor results suggest that these biomarkers might be used to triage patients for nove…”
ResultRecht, A., Connolly, J. L., Schnitt, S. J., Silver, B. J., Rose, M. A., Love, S. M., & Harris, J. R. (1988) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(88)90043-0 · Cited by 192
The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands
Tzahar, E. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00032-2 · Cited by 191
Menendez, J. A., Vazquez-Martin, A., Colomer, R., Brunet, J., Carrasco-Pancorbo, A., Garcia-Villalba, R., Fernandez-Gutierrez, A., & Segura-Carretero, A. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-80 · Cited by 191
“Patients with HER2-overexpressing cancer are associated with unfavorable prognosis, shorter relapse time, and low survival rate [26,27].”
BackgroundMolecular aspects of the metastatic cascade
Hart, I. R., Goode, N. T., & Wilson, R. E. (1989) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(89)90035-8 · Cited by 191
An ultra-high-throughput spiral microfluidic biochip for the enrichment of circulating tumor cells
Warkiani, M. E., Khoo, B. L., Tan, D. S.-W., Bhagat, A. A. S., Lim, W.-T., Yap, Y. S., Lee, S. C., Soo, R. A., Han, J., & Lim, C. T. (2014) · The Analyst · doi:10.1039/c4an00355a · Cited by 191
Ulaner, G. A., Hyman, D. M., Ross, D. S., Corben, A., Chandarlapaty, S., Goldfarb, S., McArthur, H., Erinjeri, J. P., Solomon, S. B., Kolb, H., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.172031 · Cited by 191
Defining prognosis for women with breast cancer and CNS metastases by HER2 status
Dawood, S., Broglio, K., Esteva, F. J., Ibrahim, N. K., Kau, S.-W., Islam, R., Aldape, K. D., Yu, T.-K., Hortobagyi, G. N., & Gonzalez-Angulo, A. M. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn036 · Cited by 191
HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients
Tuefferd, M., Couturier, J., Penault-Llorca, F., Vincent-Salomon, A., Broët, P., Guastalla, J.-P., Allouache, D., Combe, M., Weber, B., Pujade-Lauraine, E., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001138 · Cited by 191
“-positive status is associated with a poor prognosis”
BackgroundThe secreted tumor-associated antigen 90K is a potent immune stimulator
Ullrich, A., Sures, I., D'Egidio, M., Jallal, B., Powell, T. J., Herbst, R., Dreps, A., Azam, M., Rubinstein, M., & Natoli, C. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)32322-0 · Cited by 191
Self-citationNami, B., Maadi, H., & Wang, Z. (2018) · Cancers · doi:10.3390/cancers10100342 · Cited by 190
Nagy, P., Vereb, G., Sebestyén, Z., Horváth, G., Lockett, S. J., Damjanovich, S., Park, J. W., Jovin, T. M., & Szöllősi, J. (2002) · Journal of Cell Science · doi:10.1242/jcs.00118 · Cited by 190
“The significance of ErbB2 is underscored by its overexpression in about 30% of breast carcinomas, a phenomenon associated with poor prognosis (Slamon et al., 1987).”
BackgroundTargeting the function of the HER2 oncogene in human cancer therapeutics
Moasser, M. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210478 · Cited by 190
“The year 2007 marks exactly two decades since human epidermal growth factor receptor-2 (HER2) was functionally implicated in the pathogenesis of human breast cancer (Slamon et al., 1987).”
BackgroundThe Role of the Epidermal Growth Factor Receptor Family in Mammary Tumorigenesis and Metastasis
Kim, H., & Muller, W. J. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4706 · Cited by 190
c-erbB-2 expression in benign and malignant breast disease
Gusterson, B., Machin, L., Gullick, W., Gibbs, N., Powles, T., Elliott, C., Ashley, S., Monaghan, P., & Harrison, S. (1988) · British Journal of Cancer · doi:10.1038/bjc.1988.239 · Cited by 190
Arnedos, M., Nerurkar, A. Y., Osin, P., A’Hern, R., Smith, I. E., & Dowsett, M. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp234 · Cited by 190
Biomarkers for the clinical management of breast cancer: International perspective
Patani, N., Martin, L., & Dowsett, M. (2013) · International Journal of Cancer · doi:10.1002/ijc.27997 · Cited by 189
“HER2 overexpression/amplification occurs in 15% of cases, which is considerably less frequent than originally reported,(70) half of which are ERa-negative.(71,72) When present, it indicates poor prognosis and remains the chief predictive biomarker for the humanized monoclonal antibody trastuzumab (Herceptin; Genentech…”
BackgroundThe biology of breast carcinoma
Keen, J. C., & Davidson, N. E. (2003) · Cancer · doi:10.1002/cncr.11126 · Cited by 189
Tateishi, M., Ishida, T., Mitsudomi, T., Kaneko, S., & Sugimachi, K. (1991) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(91)90012-3 · Cited by 189
HER2 Expression Beyond Breast Cancer: Therapeutic Implications for Gynecologic Malignancies
English, D. P., Roque, D. M., & Santin, A. D. (2013) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-013-0024-9 · Cited by 188
Brodie, S. G., Xu, X., Qiao, W., Li, W.-M., Cao, L., & Deng, C.-X. (2001) · Oncogene · doi:10.1038/sj.onc.1204929 · Cited by 188
“…a poor Oncogene (2001) 20, 7514 ± 7523 ã 2001 Nature Publishing Group All rights reserved 0950 ± 9232/01 $15.00 www.nature.com/onc *Correspondence: C-X Deng; E-mail: chuxiad@bdg10.niddk.nih.gov Received 22 May 2001; revised 9 August 2001; accepted 15 August 2001 prognosis (Slamon et al., 1987).”
InfluentialTargeted Delivery of PLK1-siRNA by ScFv Suppresses Her2 + Breast Cancer Growth and Metastasis
Yao, Y.-D., Sun, T.-M., Huang, S.-Y., Dou, S., Lin, L., Chen, J.-N., Ruan, J.-B., Mao, C.-Q., Yu, F.-Y., Zeng, M.-S., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003601 · Cited by 188
Biomarkers for early detection of colon cancer.
Srivastava, S. K., Verma, M., & Henson, D. E. (2001) · PubMed · Cited by 188
Masciari, S., Dillon, D. A., Rath, M., Robson, M., Weitzel, J. N., Balmana, J., Gruber, S. B., Ford, J. M., Euhus, D., Lebensohn, A., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-1993-9 · Cited by 187
“Overexpression of HER-2 has been associated with an aggressive phenotype which includes poorly differentiated and high-grade tumors, high rates of cell proliferation, lymph-node involvement, and resistance to certain types of hormonal and chemotherapies [27, 28].”
BackgroundMendes, D., Alves, C., Afonso, N., Cardoso, F., Passos-Coelho, J. L., Costa, L., Andrade, S., & Batel-Marques, F. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0648-2 · Cited by 187
“[10]).”
Cronin, K. A., Harlan, L. C., Dodd, K. W., Abrams, J. S., & Ballard-Barbash, R. (2010) · Cancer Investigation · doi:10.3109/07357907.2010.496759 · Cited by 187
“An initial analysis reported in the literature (4, 5) on 189 primary breast cancers (103 in one sample and 86 in a second sample) estimated the prevalence of HER-2 positive tumors to be in the range of 20–25%.”
MethodBreast Cancer in African-American Women: Differences in Tumor Biology from European-American Women
Amend, K., Hicks, D., & Ambrosone, C. B. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1927 · Cited by 187
“www.aacrjournals.org 8329 Cancer Res 2006; 66: ( 17 ).”
BackgroundInfluentialMendoza, M. S., González-González, M. E., Barrera, D., Díaz, L., & García-Becerra, R. (2015) · Europe PMC (PubMed Central) · Cited by 187
Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer.
Colomer, R., Montero, S., Lluch, A. M., Ojeda, B., Barnadas, A., Casado, A., Massutí, B., Cortés-Funes, H., & Lloveras, B. (2000) · PubMed · Cited by 187
Pawlowski, V., Révillion-Carette, F., Hebbar, M., Hornez, L., & Peyrat, J. (2000) · PubMed · Cited by 187
Segatto, O., King, C. R., Pierce, J. H., Di Fiore, P. P., & Aaronson, S. A. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.12.5570 · Cited by 186
Human Adenovirus Vectors for Gene Transfer into Mammalian Cells
Hitt, M. M., Addison, C. L., & Graham, F. L. (1997) · Advances in Pharmacology · doi:10.1016/s1054-3589(08)60140-4 · Cited by 186
Shah, M. A., Jhawer, M., Ilson, D. H., Lefkowitz, R. A., Robinson, E., Capanu, M., & Kelsen, D. P. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.0770 · Cited by 186
Protein Tyrosine Phosphatases: Structure, Function, and Implication in Human Disease
Tautz, L., Critton, D. A., & Grotegut, S. (2013) · Methods in Molecular Biology · doi:10.1007/978-1-62703-562-0_13 · Cited by 157
ShcA signalling is essential for tumour progression in mouse models of human breast cancer
Ursini‐Siegel, J., Hardy, W. R., Zuo, D., Lam, S. H. L., Sanguin‐Gendreau, V., Cardiff, R. D., Pawson, T. J., & Muller, W. J. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.22 · Cited by 186
“We employed Neu/ErbB2-transformed mammary epithelial cells, as overexpression of this receptor tyrosine kinase is observed in 20–30% of human breast cancer and is inversely correlated with patient survival (Slamon et al, 1987, 1989).”
BackgroundImmunohistochemical Surrogates for Molecular Classification of Breast Carcinoma: A 2015 Update
Tang, P. T. P., & Tse, G. M.-K. (2016) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2015-0133-ra · Cited by 186
Thorpe, S. M. (1988) · Acta Oncologica · doi:10.3109/02841868809090312 · Cited by 186
HER2-directed therapy: current treatment options for HER2-positive breast cancer
Ahmed, S., Sami, A., & Xiang, J. (2015) · Breast Cancer · doi:10.1007/s12282-015-0587-x · Cited by 185
Src family kinases and HER2 interactions in human breast cancer cell growth and survival
Belsches-Jablonski, A. P., Biscardi, J. S., Peavy, D. R., Tice, D. A., Romney, D. A., & Parsons, S. J. (2001) · Oncogene · doi:10.1038/sj.onc.1204205 · Cited by 185
“Ampli®cation/overexpression of HER2, especially, has been associated with a poor patient prognosis (Slamon et al., 1987, 1989).”
BackgroundEmerging Targeted Therapies for Breast Cancer
Alvarez, R. H., Valero, V., & Hortobagyi, G. N. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4011 · Cited by 185
You, H., Ding, W., Dang, H., Jiang, Y., & Rountree, B. C. (2011) · Hepatology · doi:10.1002/hep.24450 · Cited by 185
“This type of personalized treatment has been used in the field of breast cancer for over a decade in the treatment of HER-2– positive disease with HER-2 inhibitors.(37,38) One potential factor driving poor prognosis is that c-Met activation is linked to invasion and metastasis.”
MethodChen, F., Ma, K., Madajewski, B., Zhuang, L., Zhang, L., Rickert, K., Marelli, M., Yoo, B., Turker, M. Z., Overholtzer, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06271-5 · Cited by 185
“This ultrasmall, particle-based design addresses current challenges in nanomedicine and immune targeting of HER2+ breast cancer, and achieves (1) highly specific HER2-targeted PET imaging with substantially reduced off-target accumulations in the RES or kidney over a 24 h period; (2) bulk renal clearance without exces…”
Gordon, L. I., Burke, M. A., Singh, A. T. K., Prachand, S., Lieberman, E. D., Sun, L., Naik, T. J., Prasad, S. V. N., & Ardehali, H. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m804570200 · Cited by 185
Buza, N., English, D. P.-G., Santin, A. D., & Hui, P. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.113 · Cited by 185
Wu, H., Chang, D.-K., & Huang, C.-T. (2006) · Cited by 185
ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma.
Hernán, R., Fasheh, R., Calabrese, C. R., Frank, A. J., Maclean, K. H., Allard, D., Barraclough, R., & Gilbertson, R. J. (2003) · PubMed · Cited by 185
Gut Microbiota Condition the Therapeutic Efficacy of Trastuzumab in HER2-Positive Breast Cancer
Di Modica, M., Gargari, G., Regondi, V., Bonizzi, A., Arioli, S., Belmonte, B., De Cecco, L., Fasano, E., Bianchi, F., Bertolotti, A., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1659 · Cited by 184
“The aggressive biological behavior of breast cancer overexpressing HER2 and the consequent worse clinical outcomes of patients with these tumors (1) have largely been addressed by targeting HER2.”
BackgroundMolecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer
Gu, Y., Yang, R., Zhang, Y., Guo, M., Takehiro, K., Zhan, M., Yang, L., & Wang, H. (2025) · Molecular Biomedicine · doi:10.1186/s43556-024-00239-2 · Cited by 184
Molecular Markers for Breast Cancer: Prediction on Tumor Behavior
Banin Hirata, B. K., Oda, J. M. M., Losi Guembarovski, R., Ariza, C. B., Oliveira, C. E. C. D., & Watanabe, M. A. E. (2014) · Disease Markers · doi:10.1155/2014/513158 · Cited by 184
“[28] demonstrated an association between HER-2 amplification and poor prognosis [29].”
BackgroundRas activation in human breast cancer
von Lintig, F. C., Dreilinger, A. D., Varki, N. M., Wallace, A. M., Casteel, D. E., & Boss, G. R. (2000) · Breast Cancer Research and Treatment · doi:10.1023/a:1006491619920 · Cited by 184
“While high expression of the EGF and ErbB-2 receptors are poor prognostic factors in breast cancer, it is not known whether sufficient ligands are present in breast tissue to activate the receptors and which of the signal transduction pathways activated by the receptors in cultured cells is/are activated in primary ca…”
BackgroundYin, W., Jiang, Y., Shen, Z., Shao, Z., & Lu, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021030 · Cited by 184
“hybridization positive), or both accounts for approximately 20–25% of invasive ductal carcinomas”
BackgroundThe relationship between prognostic and predictive factors in the management of breast cancer
Henderson, I. C., & Patek, A. J. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006141703224 · Cited by 184
The HER family and cancer: emerging molecular mechanisms and therapeutic targets
Sergina, N. V., & Moasser, M. M. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.10.002 · Cited by 184
HER2 as a prognostic and predictive marker for breast cancer
Cooke, T., Reeves, J., Lanigan, A., & Stanton, P. D. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_1.s23 · Cited by 184
MENSTRUAL INFLUENCE ON SURGICAL CURE OF BREAST CANCER
HRUSHESKY, W. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90956-2 · Cited by 183
The curability of breast cancer and the treatment of advanced disease
Guarneri, V., & Conte, P. F. (2004) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-004-1538-5 · Cited by 157
Harris, A. L., Nicholson, S., Richard, J., Sainsbury, C. A. R., Farndon, J., & Wright, C. (1989) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(89)90072-1 · Cited by 183
Sartor, C. I., Zhou, H., Kozlowska, E., Guttridge, K., Kawata, E., Caskey, L., Harrelson, J., Hynes, N., Ethier, S., Calvo, B., et al. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.13.4265-4275.2001 · Cited by 182
“Aberrant expression of at least two of the family members, EGFR and HER2, has been associated with poor prognosis and differential response to therapy (21, 28, 31, 44).”
BackgroundMigliaccio, A., Di Domenico, M., Castoria, G., Nanayakkara, M., Lombardi, M., de Falco, A., Bilancio, A., Varricchio, L., Ciociola, A., & Auricchio, F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0912 · Cited by 182
“This event is correlated with a poor disease prognosis ( 5 ).”
BackgroundKinome-wide Decoding of Network-Attacking Mutations Rewiring Cancer Signaling
Creixell, P., Schoof, E. M., Simpson, C. D., Longden, J., Miller, C. J., Lou, H. J., Perryman, L., Cox, T. R., Zivanovic, N., Palmeri, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.056 · Cited by 182
“In the last century, Schechter et al. (1984) and Ullrich et al. (1984) connected the discovery of the oncogene Her-2/neu to its hyperactivity in a fraction of breast cancers (Slamon et al., 1987) and the development of targeted therapies such as Tras-tuzumab (Carter et al., 1992).”
BackgroundRole of epidermal growth factor receptor in acute and chronic kidney injury
Tang, J., Liu, N., & Zhuang, S. (2013) · Kidney International · doi:10.1038/ki.2012.435 · Cited by 182
Münster, P. N., Marchion, D. C., Basso, A. D., & Rosen, N. X. (2002) · PubMed · Cited by 182
Wang, J.-H., Forterre, A. V., Zhao, J., Frimannsson, D. O., Delcayre, A., Antes, T. J., Efron, B., Jeffrey, S. S., Pegram, M. D., & Matin, A. C. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0827 · Cited by 181
“receptor tyrosine kinase signaling network; dysregulation of this network by HER2 gene amplification results in cancer [9-13].”
BackgroundWang, Z., Zhang, L., Yeung, T. K., & Chen, X. (1999) · Molecular Biology of the Cell · doi:10.1091/mbc.10.5.1621 · Cited by 181
“In particular, amplification or overexpression of the ErbB2 gene has been found in ;25–30% of human breast cancers (Slamon et al., 1987, 1989).”
BackgroundMemo mediates ErbB2-driven cell motility
Marone, R., Heß, D., Dankort, D. L., Muller, W. J., Hynes, N. E., & Badache, A. (2004) · Nature Cell Biology · doi:10.1038/ncb1134 · Cited by 182
Engineering Iron Oxide Nanoparticles for Clinical Settings
Cortajarena, A. L., Ortega, D., Ocampo, S. M., Gonzalez-García, A., Couleaud, P., Miranda, R., Belda-Iniesta, C., & Ayuso-Sacido, A. (2014) · Nanobiomedicine · doi:10.5772/58841 · Cited by 149
“Numerous research groups are interested in the functionalization of IONPs with trastuzumab, a commercial and approved antibody for breast cancer treatment [41], for the development of targeted therapeutic strategies.”
BackgroundTrastuzumab-induced cardiac dysfunction: A 'dual-hit'.
Zeglinski, M. R., Lüdke, A., Jassal, D. S., & Singal, P. K. (2011) · Europe PMC (PubMed Central) · Cited by 181
Nanotechnology for breast cancer therapy
Tanaka, T., Decuzzi, P., Cristofanilli, M., Sakamoto, J. H., Tasciotti, E., Robertson, F. M., & Ferrari, M. (2008) · Biomedical Microdevices · doi:10.1007/s10544-008-9209-0 · Cited by 181
Buttitta, F., Barassi, F., Fresu, G., Felicioni, L., Chella, A., Paolizzi, D., Lattanzio, G., Salvatore, S., Camplese, P. P., Rosini, S., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.22143 · Cited by 180
Wang, S., Saboorian, M. H., Frenkel, E., Hynan, L., Gokaslan, S. T., & Ashfaq, R. (2000) · Journal of Clinical Pathology · doi:10.1136/jcp.53.5.374 · Cited by 180
Armistead, P. M., & Thorp, H. H. (2000) · Analytical Chemistry · doi:10.1021/ac000051e · Cited by 180
Ostrowski, J. L., Sawan, A., Henry, L., Wright, C., Henry, J. A., Hennessy, C., Lennard, T. J. W., Angus, B., & Horne, C. H. W. (1991) · The Journal of Pathology · doi:10.1002/path.1711640113 · Cited by 180
Baselga, J. (2001) · Oncology · doi:10.1159/000055397 · Cited by 180
“…correlates with poor clinical outcome in both node-positive and nodenegative patients, with these patients having more aggressive disease and a shortened overall survival when compared with patients with HER2-negative tumors [Hynes and Stern 1994; Ravdin et al. 1995; Slamon et al. 1987, 1989].”
BackgroundResultMultifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden
Anglesio, M. S., Bashashati, A., Wang, Y. K., Senz, J., Ha, G., Yang, W., Aniba, M. R., Prentice, L. M., Farahani, H., Li Chang, H., et al. (2015) · The Journal of Pathology · doi:10.1002/path.4516 · Cited by 180
Dowsett, M., Procter, M., McCaskill-Stevens, W., de Azambuja, E., Dafni, U., Rueschoff, J., Jordan, B., Dolci, S., Abramovitz, M., Stoss, O., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.7939 · Cited by 180
“Its overexpression in breast cancer is a key feature of the pathobiology of the disease and is associated with poorer prognosis.(1,2) Amplification is the primary mechanism of HER2 overexpression.”
BackgroundLapatinib: Current Status and Future Directions in Breast Cancer
Moy, B., & Goss, P. E. (2006) · The Oncologist · doi:10.1634/theoncologist.11-10-1047 · Cited by 180
Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells
Neve, R. M., Sutterlüty, H., Pullen, N., Lane, H. A., Daly, J. M., Krek, W., & Hynes, N. E. (2000) · Oncogene · doi:10.1038/sj.onc.1203470 · Cited by 180
Moy, B., Kirkpatrick, P. N., Kar, S., & Goss, P. E. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2332 · Cited by 180
Barthelemy, P. A., Raab, H., Appleton, B. A., Bond, C. J., Wu, P., Wiesmann, C., & Sidhu, S. S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708536200 · Cited by 179
Luque-Cabal, M., García-Teijido, P., Fernández-Pérez, Y., Sánchez-Lorenzo, L., & Palacio-Vázquez, I. (2016) · Clinical Medicine Insights: Oncology · doi:10.4137/cmo.s34537 · Cited by 179
Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies
Goren, D., Horowitz, A., Zalipsky, S., Woodle, M., Yarden, Y., & Gabizon, A. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.625 · Cited by 179
Hendriks, B. S., Opresko, L. K., Wiley, H. S., & Lauffenburger, D. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300477200 · Cited by 179
Metadata
- Authors
- Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L.
- Affiliations
- University of California, Los Angeles (US)
- The University of Texas at San Antonio Health Science Center (US)
- Genentech (US)
- Venue
- Science
- Published
- 1987-01-09
- Volume
- 235
- Issue
- 4785
- Pages
- 177-182
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2141393790
- Cited by
- 11,760
- References
- 44
- Citations by year
- 2026: 209 · 2025: 230 · 2024: 301 · 2023: 309 · 2022: 302 · 2021: 346 · 2020: 336 · 2019: 325 · 2018: 344 · 2017: 395 · 2016: 416 · 2015: 433 · 2014: 486 · 2013: 549 · 2012: 459
- FWCI
- 103.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA36827, CA-30195)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Keywords
- gene amplification, breast cancer, prognostic factors, relapse, overall survival, lymph node-positive disease, hormone receptor status, ErbB family, epidermal growth factor receptor
- MeSH terms
- Axilla, Breast Neoplasms, DNA, Female, Gene Amplification, Humans, Lymph Nodes, Neoplasm Recurrence, Local, Nucleic Acid Hybridization, Oncogenes, Prognosis, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.